Inhibitors targeting DNA Damage Response (DDR)
DNA Damage Response Inhibition is an anti-cancer platform which could revolutionize the treatment of cancer. It works by exploiting DNA
DNA Damage Response Inhibition is an anti-cancer platform which could revolutionize the treatment of cancer. It works by exploiting DNA
IMPACT has discovered two series of novel PARP Inhibitorswith more than 60 novel compounds that are many folds more potent than AZD2281
IMPACT has discovered three series of novel Hedgehog pathway inhibitors and has identified more than 10 compounds that are 10-100 folds more potent than the approved Hedgehog inhibitor GDC-044
IMPACT has discovered two series of novel small molecular microtubule inhibitors, and selected IMP3138 as a clinical candidate for further development.
The appointment was effective on Oct.01, 2018. The appointment will help the development o
Impact Therapeutics is a privately held clinical-stage biopharmaceutical company incorporated in Nanjing, China, dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality.
MOREIMPACT regards employees as the most valuable asset of the company, willing to absorb all outstanding and potential talents, and provides a broad career development space for each employee.